Our data are also supported by data from the neo-adjuvant setting where a single injection of pembrolizumab in resectable stage III or IV melanoma patients resulted in the expansion of Ki67+ PD-1+ CTLA-4+ CD8+ T-cells in the peripheral blood of patients 7 days post injection. Here, PDCD1 is linked to melanoma.